Quantitative and Qualitative Disclosures About Market Risk
−Removed: We are subject to price risk for our raw materials, the most significant of which relates to the cost of polypropylene and nitrile used in the manufacturing processes of our Products & Healthcare Services segment.
−Removed: Prices of the commodities underlying these raw materials are volatile and have fluctuated significantly in recent years and in the future may contribute to fluctuations in our results of operations.
−Removed: The ability to hedge these commodity prices is limited.
−Removed: In the normal course of business, we are exposed to foreign currency translation and transaction risks.
−Removed: Our business transactions outside of the U.S.
−Removed: are denominated in the euro, Malaysian ringgit, Mexican peso, thai baht and
−Removed: other currencies.
−Removed: We may use foreign currency forwards, swaps and options, where possible, to manage our risk related to certain foreign currency fluctuations.
−Removed: As of December 31, 2024 and 2023, we held contracts with notional amounts of $43 million and $78 million to exchange the U.S.
−Removed: dollar, euro, thai baht and other currencies.
−Removed: See Note 11 in the Notes to Consolidated Financial Statements.
−Removed: We are exposed to market risk from changes in interest rates related to our borrowing under our Revolving Credit Agreement, and related to our participation in the Receivables Sale Program, and RPA.
−Removed: Excluding deferred financing costs and third party fees, we had $326 million in borrowings under our Term Loan A, $511 million in borrowings under our Term Loan B, no outstanding borrowings under our Revolving Credit Agreement, $70 million of uncollected accounts receivable under our Receivables Sale Program, and no uncollected accounts receivable under our RPA at December 31, 2024.
−Removed: After considering the effects of our interest rate swap agreement (See Note 11 in the Notes to Consolidated Financial Statements), we estimate an increase in interest rates of 100 basis points would result in a potential reduction in future pre-tax earnings of approximately $6.1 million per year based on our borrowings and uncollected accounts receivable sold under our Receivables Sale Program at December 31, 2024.
+Added: We are exposed to market risk from changes in interest rates related to our borrowing under our Revolving Credit Agreement, and related to our participation in the Amended Receivables Sale Program.
+Added: Excluding deferred financing costs and third party fees, we had $326 million in borrowings under our Term Loan A, $511 million in borrowings under our Term Loan B, $204 million in outstanding borrowings under our Revolving Credit Agreement and $134 million of uncollected accounts receivable under our Amended Receivables Sale Program at December 31, 2025.
+Added: After considering the effects of our interest rate swap agreement (See Note 11 in the Notes to Consolidated Financial Statements), we estimate an increase in interest rates of 100 basis points would result in a potential reduction in future pre-tax earnings of approximately $9.2 million per year based on our borrowings and uncollected accounts receivable sold under our Amended Receivables Sale Program at December 31, 2025.
Financial Statements and Supplementary Data
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.